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Abstract
Objectives: Genome-wide association studies have facilitated the identification of over 30 susceptibility loci for rheumatoid
arthritis (RA). However, evidence for a number of potential susceptibility genes have not so far reached genome-wide
significance in studies of Caucasian RA.
Methods: A cohort of 4286 RA patients from across Europe and 5642 population matched controls were genotyped for 25
SNPs, then combined in a meta-analysis with previously published data.
Results: Significant evidence of association was detected for nine SNPs within the European samples. When meta-analysed
with previously published data, 21 SNPs were associated with RA susceptibility. Although SNPs in the PTPN2 gene were
previously reported to be associated with RA in both Japanese and European populations, we show genome-wide evidence
for a different SNP within this gene associated with RA susceptibility in an independent European population (rs7234029,
P= 4.461029).
Conclusions: This study provides further genome-wide evidence for the association of the PTPN2 locus (encoding the T cell
protein tyrosine phosphastase) with Caucasian RA susceptibility. This finding adds to the growing evidence for PTPN2 being
a pan-autoimmune susceptibility gene.
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Introduction
A European Union funded project, the AutoCure consortium
(www.autocure.org) involves collaboration between 26 European
multinational partners in the search for improved understanding
of inflammatory rheumatic diseases. To co-ordinate the
collection of DNA for analysis, the Genetic Repository for
AutoCure (GRACE) was established. GRACE incorporates
rheumatoid arthritis (RA) patient samples from Denmark,
France, Germany, Greece, Ireland, Sweden and UK, and
controls from all populations except Denmark. A recent
publication used the GRACE cohort to investigate RA loci
[1]. Since then, additional samples have been added to
GRACE, and evidence has emerged from other well powered
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RA cohorts for association to additional SNPs, although not all
of these have achieved genome wide significance (P,561028).
Therefore, this study aimed firstly to continue characterising the
GRACE cohort for confirmed RA susceptibility loci, and
secondly to genotype SNPs for provisional RA loci in GRACE
and perform a meta-analysis using previously published data to
investigate whether any can be confirmed at genome wide
significance, therefore providing further evidence for the role of
these variants in the susceptibility of RA.
Methods
Cohorts
All samples included in this analysis were of European ancestry,
with RA as defined by the 1987 American College of Rheuma-
tology classification criteria for genetic studies [2]. Demographics
were collected where available. A total of 4286 RA subjects were
included from nine centres across Europe. To minimise potential
problems with population stratification, a total of 5642 controls
were obtained from the same populations as each GRACE cohort,
with the exception of the Danish samples for which controls were
unavailable. To account for this the genotype counts between the
Swedish and Danish cases were compared for each SNP using a x2
test (or Fisher’s exact test when genotype counts were less than 10)
and found to not significantly differ (Bonferroni corrected
P,0.002, data not presented) as seen previously for these cohorts
[1]. The Scandinavian cases were therefore combined prior to
analysis with Swedish controls. Similarly, the UK cases from
Manchester and Birmingham were found not to differ significant-
ly, were combined and compared to controls available via the
Wellcome Trust Case Control Consortium 2 (WTCCC2). The
Dublin control data was obtained from a previous study [3].
Ethical approval was obtained via written informed consent and in
accordance with the Declaration of Helsinki from the following
bodies: North West Multicentre Research Ethics Committee
(Manchester, UK), Sandwell and West Birmingham Research
Ethics Committee and Solihull Research Ethics Committee
(Birmingham, UK), Regional Ethics Committee at the University
Hospital of Umea˚ (Umea˚, Sweden), Ethical Committee of the
Capital Region (Copenhagen, Denmark), St. Vincent’s University
Hospital Ethics Committee (Dublin, UK), Research Ethics
Committee of the Faculty of Medicine, University of Crete (Crete,
Greece), Local Ethical Committee of the Hannover Medical
School (Hannover, Germany), Charite´ Local Ethical Committee
(Berlin, Germany), Ethics Committee of Hoˆpital Kremlin-Biceˆtre
(Paris, France).
Genotyping
Twenty-five markers were selected to further characterise the
GRACE cohort and validate unconfirmed RA SNPs based on
recent findings [4–6]. Group 1 SNPs have previously been shown
to have genome-wide association with RA susceptibility
(P,561028) in a meta-analysis published by Stahl and colleagues
[6], group 2 SNPs have prior evidence at genome-wide
significance level in other RA studies, and group 3 SNPs are
potential RA loci identified in the Stahl meta-analysis which have
not yet been confirmed at genome-wide significance (see Tables 1
and 2). Sequenom MassArray multiplex assays were designed and
genotyping performed using iPLEX chemistry as per the
manufacturer’s instructions (Sequenom Inc., USA). Only SNPs
with genotyping success rate .95% and samples with success rate
.90% were included in the analysis.
Statistical Analysis
Allele counts and genotype frequencies were calculated for each
population, analysed using an additive genetic model, and
combined in a meta-analysis of all GRACE cohorts. Published
data was used to perform a second meta-analysis with the GRACE
data [6], Stahl’s study selected as it is the largest and most
comprehensive meta-analysis of RA to date. A fixed effect model
(Mantel-Haenszel method) was used to perform the meta-analysis,
with cohorts weighted based on the amount of information they
contain. Where evidence for between cohort heterogeneity (I2) was
observed (P,0.05) a random effects model (DerSimonian and
Laird method) was used, as indicated in the results.
Power calculations were performed at the 5% significance level
using previously published effect sizes and for the results of the
second meta-analysis using the software package Quanto v1.2
(http://hydra.usc.edu/gxe). All analysis was undertaken using the
statistical software packages Stata v10 (StataCorp 2009) and Plink
v1.07 [7].
Results and Discussion
Cohort Characteristics and Quality Control
The AutoCure consortium facilitated the establishment of
GRACE, a large collection of pan-European DNA samples. A
total of 3195 RA subjects (Manchester 820, Birmingham 95,
Umea˚ 665, Copenhagen 286, Paris 307, Crete 402, Hannover
199, Berlin 265, Dublin 156) and 5378 controls passed QC with
genotyping success rate .90%. The SNPs selected for this study
were based on a recent publication that identified seven novel RA
susceptibility loci at genome-wide significance and additional
markers with suggestive evidence for association [6]. In the
GRACE analysis, one SNP (rs540386 in TRAF6) in the Cretan
cohort showed significant deviations from Hardy-Weinberg
equilibrium in controls and was therefore excluded from the
analysis for these samples. There was no data available for
rs10865035 in AFF3 (nor an available proxy) in the UK control
data from the WTCCC2, therefore this SNP was excluded in the
UK samples. Two SNPs in the UK control data from the
WTCCC2 were unavailable, however perfect proxies (r2 = 1) were
used for rs10488631 (proxy rs12531711) and rs26232 (proxy
rs2288786). The RA cases from Dublin were added to the
GRACE collection at a later stage and were therefore genotyped
separately. For these samples, an additional five SNPs failed
genotyping QC (rs26232, rs3093023, rs6859219, rs706778 and
rs951005) and were therefore excluded from the analysis for the
Dublin samples. Three group 3 SNPs failed QC due to genotyping
success of ,95% (rs10919563 near PTPRC, rs12746613 near
FCGR2A, and rs3184504 near SH2B3).
Meta-analysis of GRACE Cohorts
An association analysis of the additive genetic model for each
SNP genotyped in the GRACE cohorts was initially performed
(data not presented). These results were then combined in a meta-
analysis, which replicated the association of nine SNPs with RA
(P,0.05, Table 1). The strongest associations were seen with SNPs
rs26232 (GIN1 P= 4.6861024), rs874040 (RBPJ P= 2.1861024)
and rs1980422 (CD28 P= 2.9861024).
Overall Meta-analysis, Including Previously Published
Data
The meta-analysis of previously published data with the new
GRACE genotyping provided further evidence for the role of 21
SNPs in the susceptibility of RA in European populations and
improved the previously published association signal for eight
PTPN2 Associated with European RA Susceptibility
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SNPs (Table 2) [4–6]. We improved the association at RBPJ
(rs874040) and IRF5 (rs10488631); replicate the association at
ANKRD55-IL6ST (rs6859219), C5orf30/GIN1 (rs26232) and CCR6
(rs3093023); and replicate the association at PXK-FAM107A
(rs13315591), although the evidence for this locus has reduced
and thus needs to be further investigated in an independent
population. Other SNPs genotyped resulted in reduced association
signals. Three SNPs (rs10488631, rs4535211 and rs706778) had
significant between-study heterogeneity, primarily due to the
broad distribution of effect sizes in different directions between
studies.
Notably, we increased the previously reported association of a
SNP [1,6] within an intron of PTPN2 to a genome-wide
significance level for the first time in a European population of
RA patients (rs7234029, OR = 1.15, P= 4.4461029). This same
variant is highly associated with juvenile idiopathic arthritis [8,9].
More recently another SNP within PTPN2 (rs2847297) was found
to be associated with RA in a Japanese population at the genome-
wide significance level (P= 2.261028) [10], and a further SNP
(rs62097857) in low linkage disequilibrium with rs7234029 has
recently been implicated (P= 4.461026) in a large Caucasian
study of RA [11]. However, the SNP detailed in this publication
by Eyre et al is in low LD with rs7234029 tested here, and as this
region fails to reach the significance thresholds set by Eyre et al
there is little detail of the PTPN2 results within the article or
supplementary files published, inhibiting more detailed compar-
isons. This highlights the need for further investigation of the role
of PTPN2 in RA pathogenesis in both European and Asian
populations. PTPN2 is a non-receptor tyrosine-protein phospha-
tase similar to PTPN22. It encodes the T cell protein tyrosine
phosphastase, which is known to act as a negative regulator of the
JAK/STAT signalling pathways downstream of cytokines such as
IL2, and thus may play an important role in T cell activation [12].
The results presented here add to the mounting evidence in RA
[10,11], along with studies in Crohn’s disease [13], type 1 diabetes
[14], and juvenile idiopathic arthritis [9], to provide evidence for
PTPN2 being a pan-autoimmune susceptibility gene.
Interestingly evidence for rs4535211, within the negative
regulator of B cell receptor signalling (PLCL2) gene, was increased
from P= 0.001 in the Stahl meta-analysis to P= 9.9261028,
approaching genome-wide significance levels. This SNP has been
highlighted in a recent psoriatic arthritis (PsA) study as being
associated with early age of onset disease, although the allele that
confers protection for RA here is a risk allele for PsA [15].
One limitation to this work is that the collection of samples
utilised contains both seropositive and seronegative RA patients.
There is continued debate surrounding the genetic differences
between RA patients with different serology [16,17], and therefore
Table 1. Results from initial (GRACE only) meta-analysis.
SNP Gene Case/Control MAF Case MAF Control Het P OR (95% CI) x2P
Group 1: SNPs with previous evidence of genome-wide association with RA susceptibility from Stahl meta-analysis
rs10488631 IRF5 3193/5018 0.12 0.12 0.748 1.06 (0.95,1.17) 0.297
rs13315591 PXK-FAM107A 3194/5020 0.07 0.07 0.798 1.03 (0.91,1.18) 0.612
rs26232 C5orf30/GIN1 3038/5014 0.3 0.33 0.98 0.88 (0.82,0.94) 4.68 61024
rs3093023 CCR6 3037/5020 0.47 0.44 0.321 1.09 (1.02,1.17) 0.012
rs6859219 ANKRD55 3026/4950 0.18 0.21 0.792 0.87 (0.8,0.95) 0.002
rs706778 IL2RA 3007/4998 0.43 0.41 0.157 1.04 (0.97,1.11) 0.301
rs874040 RBPJ 3195/5003 0.32 0.29 0.235 1.14 (1.07,1.23) 2.18 61024
rs951005 CCL21 2857/4857 0.16 0.17 0.72 0.92 (0.84,1.01) 0.069
Group 2: SNPs with previous evidence of genome-wide association with RA susceptibility from other studies
rs11586238{ CD2,CD58 3195/5015 0.25 0.23 0.292 1.12 (1.03,1.21) 0.005
rs13031237{ REL 3191/4952 0.37 0.36 0.147 1.06 (0.99,1.13) 0.125
rs1980422{ CD28 3093/4960 0.25 0.23 0.663 1.15 (1.07,1.25) 2.9861024
rs2736340{ BLK 3194/5021 0.26 0.24 0.655 1.14 (1.05,1.22) 0.001
rs548234{ PRDM1 3192/5010 0.33 0.33 0.062 0.87 (0.8,0.95) 0.205
Group 3: SNPs not previously associated with RA susceptibility to a genome-wide significance level
rs10865035 AFF3 3189/2286 0.48 0.47 0.539 1.02 (0.94,1.11) 0.61
rs11203203 UBASH3A 3176/5009 0.38 0.37 0.196 1.00 (0.93,1.07) 0.911
rs11594656 IL2RA 3195/5014 0.24 0.25 0.534 0.98 (0.91,1.06) 0.579
rs394581 TAGAP 3190/4942 0.28 0.3 0.531 0.91 (0.84,0.98) 0.008
rs42041 CDK6 3186/5015 0.25 0.24 0.277 1.06 (0.98,1.14) 0.148
rs4535211 PLCL2 3195/5107 0.46 0.48 0.102 0.96 (0.9,1.03) 0.237
rs540386 TRAF6 2787/4600 0.13 0.14 0.071 1.05 (0.98,1.12) 0.207
rs7234029 PTPN2 3189/5014 0.18 0.16 0.092 1.15 (1.05,1.26) 0.002
rs7543174 UBE2Q1 3194/4951 0.18 0.18 0.056 1.03 (0.95,1.12) 0.508
SNPs allocated to group 1, 2 or 3 based on previously published evidence. The SNPs{ in group 2 do not reach genome-wide significance in Stahl et al used in meta-
analysis [6] (Table 2), but have in prior publications [4,5]. Het P= meta-analysis heterogeneity x2 P value, OR = odds ratio calculated using fixed or random* effects meta-
analysis.
doi:10.1371/journal.pone.0066456.t001
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the GRACE cohort may only have the power to detect
associations with SNPs involved in both types of RA. A further
limitation is the potential for population stratification and bias by
combining Danish and Swedish cases in the analysis with only
Swedish controls. Although the relatively small numbers of
Scandinavian RA cases available reduces our power to detect
differences at these SNPs, no evidence for bias within these cohorts
was observed (lack of significant differences in genotype frequen-
cies between the cases), in concordance with previous studies in
these samples [1]. Unfortunately the GRACE cohort only has
limited genotyping data available and therefore insufficient
unlinked markers for population stratification methods such as
genomic control to test this more thoroughly.
This study utilises the large GRACE resource of up to 10,000
European RA cases and controls to provide further evidence for
the role of 21 SNP markers in the susceptibility to RA in European
populations. This has enabled detection of genome-wide evidence
for the association of a SNP within an intron of PTPN2 which,
along with recent investigations of different SNPs at this locus,
highlights the need for more comprehensive investigation at this
locus in large RA cohorts from multiple ethnicities. Further fine-
mapping of these regions will be required to identify the causal
variants involved in RA susceptibility. Such work is now possible
within the Immunochip, a custom Illumina Infinium genotyping
chip designed to fine-map genomic loci involved in multiple
autoimmune diseases [18].
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